We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

One of the approvals is for Ebglyss, a treatment for atopic dermatitis that could displace the current market leader, ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Both Kisunla and Ebglyss hold the potential to become blockbuster drugs. Investors shouldn't overlook Lilly's pipeline, ...

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eli Lilly (NYSE:LLY) received approval from the Hong Kong government to launch its weight-loss drug—Mounjaro, with sales ...

Druckenmiller has been a net seller of Lilly stock for several consecutive quarters. Furthermore, his fund dumped most of its ...